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Abstract
Objective: Axon reflex-mediated neurogenic vasodilatation in response to cutaneous heating may reflect early, pre-clinical
small fibre dysfunction. We aimed to evaluate the distribution of the vascular flare area measured by laser doppler imaging
(‘‘LDIFLARE area’’) in type 1 diabetes and in healthy volunteers.
Research and Methods: Concurrent with clinical and electrophysiological examination to classify diabetic sensorimotor
polyneuropathy (DSP), LDIFLARE area (cm
2) was determined in 89 type 1 diabetes subjects matched to 64 healthy volunteers.
We examined the association and diagnostic performance of LDI with clinical and subclinical measures of DSP and its
severity.
Results: Compared to the 64 healthy volunteers, the 56 diabetes controls without DSP had significantly lower LDIFLARE area
(p=0.006). The 33 diabetes cases with DSP had substantially lower LDIFLARE area as compared to controls without DSP
(p=0.002). There was considerable overlap in LDIFLARE area between all groups such that the ROC curve had an AUC of 0.72
and optimal sensitivity of 70% for the detection of clinical DSP. Use of a subclinical definition for DSP, according to
subclinical sural nerve impairment, was associated with improved AUC of 0.75 and sensitivity of 79%. In multivariate analysis
higher HbA1c and body mass index had independent associations with smaller LDIFLARE area.
Conclusions: Axon reflex-mediated neurogenic vasodilatation in response to cutaneous heating is a biomarker of early
nerve dysfunction in DSP. Its independent association with glycemic exposure in diabetes subjects and both glycemic
exposure and BMI in healthy volunteers highlights the existence of small-fibre dysfunction in the natural history of DSP.
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Introduction
The rising incidence of diabetes and its negative impact on
quality of life highlights the urgent need to develop biomarkers of
early nerve damage. Diabetic sensorimotor polyneuropathy (DSP)
– the most common complication in type 1 diabetes – represents
diffuse symmetrical and length dependent injury to peripheral
nerves and predisposes patients to neuropathic pain, sensory and
motor dysfunction, and other complications[1–6]. The under-
diagnosis of neuropathy delays early management necessary to
improve glycemic control and the prevention of neuropathy-
related sequelae [4,7].
The prevailing concept of the natural history of DSP is that
early nerve damage begins in small thinly myelinated Ad and
unmyelinated C-type nerve fibres [8,9]. The gold-standard
method to evaluate morphological change in small nerve fibres
has been the skin biopsy [10], however, this technique is limited by
cost, invasiveness, provides no information about the function of
nerve fibres and cannot be employed as a generalized screening
test in all patients with type 1 diabetes. Currently, there is an
urgent need for the application of a valid clinical screening test to
detect early small fibre dysfunction.
Out of the current recommendations for detection of neurop-
athy, evaluation of the Semmes-Weinstein 10 g monofilament
examination was shown to be a valid tool with good performance
to identify DSP [11,12]. Though much work has been accom-
plished to define the validity of simple sensory testing on physical
examination for use in the clinic, there are limitations in specificity
as pre-clinical, predictive markers to detect the onset of
neuropathy [12–14].
As an alternative, axon reflex-mediated neurogenic vasodilata-
tion (‘‘LDIFLARE’’) is directly related to nociceptive C-fibre
function and has shown promise as a marker of DSP [15,16]. A
heat stimulus causes an increase in blood flow for several
centimeters around the site of skin irritation through stimulation
of peripheral C-fibre branches in surrounding skin. This activation
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nerve (antidromic transmission) triggering the release of vasoactive
peptides to increase the diameter of cutaneous vessels. The
neurogenic reflex depends on intact sensory innervations of the
skin because the spread of the flare is largely ablated by the
administration of local anesthesia, supporting that the LDIFLARE
area is neurogenic in nature [17–19].
As the first step to ultimately evaluate LDI as a screening test
that can predict the future onset of DSP, we sought to determine
the performance of LDIFLARE area to identify the presence or
absence of DSP in the cross-sectional baseline evaluation of an
ongoing longitudinal cohort study of individuals with type 1
diabetes and healthy volunteers. We used a gold-standard
definition for DSP based on nerve conduction studies but also
sought to establish the diagnostic performance of a subclinical
definition of DSP according to abnormality in individual nerve
conduction parameters.
Methods
Eighty-nine participants with type 1 diabetes were accrued from
the Diabetes and Endocrinology Clinic and Diabetic Neuropathy
Clinic at the Toronto General Hospital/University Health
Network. Sixty four healthy volunteers, recruited through friends
and family members of participants with diabetes and community
advertisements, were part of a cohort study funded by the Juvenile
Diabetic Research Foundation (operating grant No.17-2008-715).
The main objective of this study was to identify the concurrent
validity of laser doppler imaging (LDI) in the cross-sectional
identification of DSP and its predictive validity in the longitudinal
analysis of those without baseline neuropathy. The current report
evaluates the cross-sectional data from examinations conducted
between November 2008 and May 2010.
Subject Selection and Evaluation
We aimed to include type 1 diabetes subjects with a spectrum of
nerve damage, from lack of detectable nerve injury to severe DSP.
This was accomplished by way of stratified accrual according to
the Toronto Clinical Neuropathy Score (TCNS), a validated
grading system to evaluate history and physical exam components
that permitted tracking of the numbers of subjects likely to have
absent, mild, moderate and severe neuropathy at the time of study
accrual [13,20]. Subjects were included if they had type 1 diabetes,
were 18 years or older, provided informed consent and did not
have neuropathy attributable to causes other than diabetes. The
causes of neuropathy were excluded by detailed medical history,
family history, history of toxin exposure, renal failure or presence
of abnormal serum or urine protein electrophoresis. Healthy
volunteers were selected according to age matching (by decade of
life) and gender matching with the type 1 diabetes participants.
A comprehensive medical and neurologic evaluation of each
participant and healthy volunteer involved a clinical neurological
history and examination with a focus on lifestyle factors and
comorbidities. Biochemical tests included glycated hemoglobin
A1C, serum lipids and urinary albumin excretion.
Assessment Of Axon–Reflex Mediated Neurogenic
Vasodilatation In Response To Cutaneous Heating By The
Laser Doppler Imaging Flare Technique (‘‘LDIFLARE’’)
The surface skin temperature of the dorsum of the foot was
standardized to 32uC using a warm blanket. We subsequently used
a standard skin-heating probe (Moore instruments Ltd, Axminster,
UK), a 0.64 cm
2 circular metal disc that was well-affixed to the
skin above the first metatarsal area on the dorsum of the foot, that
heated the skin to 44uC for 20 minutes. After probe removal the
LDIFLARE was measured by LDI using the moorLDI2
TM (Moor
Instruments Ltd, Axminster, UK) [15]. The laser head of the LDI
apparatus was positioned at a fixed distance of 30 cm from the
dorsum of the foot and scanned an area of 6 cm66 cm (36 cm
2).
The LDI apparatus used a scanning doppler infrared laser beam
with a wavelength of 785 nm, sufficient to penetrate skin to
register the movement of blood cells in dermal capillaries. The
36 cm
2 area represented a 2566256 pixel resolution with each
pixel itself representing a measurement of the velocity of tissue
blood flow. The total scanning time was less than five minutes per
examination. The flare area (cm
2) was calculated using Moor LDI
software (version 3.11).
Classification Of Diabetic Sensorimotor Polyneuropathy
(DSP) Cases And Controls
Nerve conduction study (NCS) testing involved examination of
unilateral dominant-side sural and peroneal nerves of the lower
limb. Two sural parameters were studied, the sural nerve action
potential amplitude and the sural nerve conduction velocity).
Three peroneal nerve parameters were tested – the distal
compound muscle action potential amplitude and the f-wave
latency from ankle stimulation, and the conduction velocity from
fibular head stimulation. The test was performed using the
Counterpoint instrument (Natus Medical, San Carlos, CA)
meeting the standards of the American Association for Neuro-
muscular and Electrodiagnostic Medicine and the Canadian
Society of Clinical Neurophysiology.
DSP was established by clinical and electrophysiological criteria
proposed by the American Association of Neurology, the
American Academy of Electrodiagnostic Medicine and the
American Academy of Physical Medicine and Rehabilitation.
Based on this consensus, we defined electrophysiological abnor-
mality according to two criteria; the first was the ‘‘England
criteria’’ which included the presence of at least one abnormal
nerve conduction parameter in both sural and peroneal nerve
distributions in combination with the presence of more than one
symptom (numbness, tingling, weakness, foot pain, or ataxia) or
sign (abnormal knee or ankle reflexes, temperature, light touch,
monofilament, or vibration sensation) [21]. We applied age- and
height-adjusted criteria for sural and peroneal amplitudes and
conduction velocities, which were scored as normal or abnormal
according to laboratory testing values [22]. To meet criteria for
DSP, the neurological manifestations must have been in keeping
with a length-dependent symmetrical c pattern of onset and
progression. The second case definition was for subclinical DSP,
defined by the presence of one or more abnormalities in sural
nerve amplitude or conduction velocity (‘‘sural nerve criteria’’).
Among individuals with diabetes, subjects that did not meet
‘‘England criteria’’ for DSP were labeled as ‘‘controls’’. To
investigate a definition for subclinical nerve injury the diabetes
control subjects were further divided into two groups based on
‘‘sural nerve criteria’’: one group had normal sural nerve
parameters and the other group included individuals with one or
more abnormalities in sural nerve amplitude or conduction
velocity. Subjects that met the ‘‘England criteria’’ for DSP were
labeled as ‘‘cases’’ and designated into three groups by increasing
neuropathy severity: mild, moderate and severe. The criteria for
mild neuropathy were two or more abnormal nerve conduction
parameters in the lower limb (sural and peroneal nerve
distributions), and moderate and severe neuropathy were defined
by four and five abnormal parameters, respectively.
Neurogenic Vasodilatation in Type 1 Diabetes
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Analysis was performed using SAS (version 9.2 for windows).
Differences in clinical categorical variables between healthy
volunteers and individuals with type 1 diabetes with and without
DSP were assessed using the x
2 test while continuous variables
were assessed by ANOVA. The results are expressed as mean 6
SD. Among the baseline variables (Table 1) the TCNS score was
not normally distributed. As such, the data are presented as
median and interquartile ranges. Dependent predictor variables
for the univariate linear regression models with LDIFLARE area
were assessed by standard regression diagnostics. Receiver
operating characteristic (ROC) curves were generated for LDI-
FLARE area to determine the area under the curve (AUC) and for
inspection of the optimal threshold value to detect DSP by the
‘‘England criteria’’ and the subclinical definition of neuropathy
using ‘‘sural nerve criteria’’.
Results
We characterized 153 subjects in this cross-sectional analysis,
consisting of 64 healthy volunteers, 56 individuals with type 1
diabetes without nerve damage and 33 individuals with type 1
diabetes and DSP. As shown in Table 1, individuals with type 1
diabetes and DSP were older, had longer diabetes duration, higher
body mass index and weight, and higher systolic and diastolic
blood pressure compared to both healthy volunteers and type 1
diabetes controls without DSP. Among the type 1 diabetes
subjects, HbA1c was higher but LDL cholesterol was lower
compared to healthy volunteers. The Toronto Clinical Neurop-
athy Score (TCNS), a clinical indicator of the severity of nerve
injury, was also higher in subjects with type 1 diabetes compared
to healthy volunteers. Consistent with this finding, sural and
peroneal nerve amplitude potentials were lower and conduction
velocities were slower in subjects with type 1 diabetes compared to
healthy volunteers. The wide interquartile range of TCNS scores
and proportionately large standard deviations for nerve conduc-
tion parameters in type 1 diabetes cases with DSP indicated a wide
distribution of nerve injury. The LDIFLARE area was smaller in
subjects with type 1 diabetes compared to healthy volunteers
(ANOVA p-value for trend, p,0.0001).
To further explore the relationship of the LDIFLARE area
between healthy volunteers and subjects wtih type 1 diabetes, we
Table 1. Clinical characteristics of the 64 healthy volunteers and of the 89 type 1 diabetes participants according to diabetic
sensorimotor polyneuropathy status.
Baseline Clinical Characteristic
Healthy volunteers
(n=64)
Type 1 diabetes
(n=89)
ANOVA P-value
for trend*
Controls without DSP
(n=56)
Cases with DSP
(n=33)
Female sex (%) 34 (53%) 29 (53%) 17 (52%) 0.99
Age (yr) 38.9 6 17.6 34.9 6 14.8 50.0 6 14.3 0.0001
Diabetes Duration (yr) – 17.6 6 14.0 31.4 6 13.5 ,0.0001
Current/Recent
Smoking, n(%)
13 (21%) 7 (13%) 7 (21%) 0.43
Body mass index (kg/m
2) 24.7 6 4.6 25.3 6 4.4 28.9 6 5.0 0.001
Height (m) 1.7 6 0.1 1.7 6 0.1 1.7 6 0.1 0.14
Weight (kg) 71.7 6 15.9 76.9 6 15.2 85.5 6 19.7 0.005
Systolic Blood
Pressure (mmHg)
124 6 14 125 6 14 137 6 17 0.0001
Diastolic Blood Pressure (mmHg) 76 6 11 71 6 87 3 6 9 0.01
HbA1c (%) 5.5 6 0.4 7.4 6 1.3 8.7 6 2.1 ,0.0001
Total cholesterol (mmol/L) 4.9 6 1.1 4.6 6 0.8 4.6 6 1.6 0.29
LDL cholesterol (mmol/L) 2.9 6 0.8 2.5 6 0.7 2.4 6 1.1 0.01
HDL cholesterol (mmol/L) 1.5 6 0.5 1.7 6 0.4 1.6 6 0.5 0.18
Triglycerides (mmol/L) 1.1 6 0.6 0.9 6 0.7 1.2 6 0.9 0.16
Toronto Clinical Neuropathy Score, Median
[IQR]
{
0 [0,2] 2.5 [1.5, 6.0] 10 [7,14] ,0.0001
Sural nerve amplitude
potential (mV)
18 6 81 1 6 52 6 2 ,0.0001
Sural nerve conduction
velocity (m/s)
51 6 54 6 6 44 0 6 3 ,0.0001
Peroneal nerve amplitude potential (mV) 6 6 26 6 22 6 1 ,0.0001
Peroneal nerve conduction velocity (m/s) 48 6 34 3 6 33 6 6 5 ,0.0001
LDIFLARE Area (cm
2)
{ 3.4 6 1.9 2.4 6 1.4 1.4 6 0.6 ,0.0001
Plus-minus values are means 6 SD. [IQR] represents the interquartile range.
*P values for categorical variables were calculated with the x2 test, and ANOVA was used for continuous variables.
{TCNS, Toronto clinical Neuropathy score. Scores of 0–5 are generally considered to represent low likelihood of DSP, 6–8 represents likelihood of mild neuropathy, 9–12
represent likelihood of moderate neuropathy, while 12–19 represent severe neuropathy.
{Axon-reflex mediated neurogenic vasodilatation by the laser doppler imaging flare method.
doi:10.1371/journal.pone.0034807.t001
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ries (Figure 1). We observed a significant inverse relationship
between LDIFLARE area and the ordinal categories of healthy
volunteers, type 1 diabetes controls without DSP divided into
those with and without evidence of subclinical sural nerve injury,
and type 1 diabetes cases with DSP divided into those with mild,
moderate, and severe neuropathy according to the number of
abnormal nerve conduction parameters (ANOVA p-value for
trend, p,0.001). Compared to healthy volunteers, the type 1
diabetes controls without DSP (made up of the second and third
box-and-whisker plots in Figure 1) had significantly lower
LDIFLARE area (p=0.006). To determine if controls without
evidence of subclinical large fibre impairment, as indicated by
normal sural nerve conduction study parameters, have a different
distribution of LDIFLARE area than controls who have minor
impairments in sural nerve conduction, we separated the
distributions as indicated in the second and third box-and-whisker
plots in Figure 1. Even those diabetes controls without evidence of
subclinical nerve injury had lower mean LDIFLARE area as
compared to healthy volunteers (p=0.03). Those controls with a
single abnormal sural nerve conduction parameter had similar
LDIFLARE area to those with normal sural parameters (p=0.49).
However, cases with DSP had substantially lower LDIFLARE area
as compared to these type 1 diabetes controls without DSP
(p=0.0002). Among type 1 diabetes cases the LDIFLARE area was
not incrementally different in the three groups designated by
increasing neuropathy severity. Despite the overall significant
trend of smaller LDIFLARE area with increasing nerve injury
shown in Figure 1, we also noted substantial overlap in the
distribution of LDIFLARE area between all groups.
In view of the significant relationship of LDIFLARE area with
diabetes and neuropathy, we pursued ROC curve analysis to
examine the performance of LDI to detect DSP among subjects
with type 1 diabetes (Figure 2). Employing the ‘‘England criteria’’
for the DSP case definition the area under the ROC curve was
0.72 (Figure 2, PanelA), but the optimal threshold value for ruling
in DSP of #1.90 cm
2 had limited diagnostic performance
(sensitivity 70% and specificity 66%). Acknowledging that the
LDIFLARE area represents small fibre dysfunction,we defined an
alternate phenotype representing earlier nerve injury than would
be defined by the ‘‘England criteria’’. In this analysis we defined
subclinical sural nerve impairment according to the ‘‘sural nerve
criteria’’ and determined that the ROC curve had a higher AUC
of 0.75 (Figure 2, Panel B), and an optimal threshold value (also
#1.90 cm
2) that had a higher sensitivity of 79%, but a lower
specificity of 60% when compared to the ROC curve generated
for the ‘‘England criteria’’ outcome.
We examined the association between LDIFLARE area with the
clinical and biochemical variables listed in Table 1, and report the
variables that were significantly associated with LDIFLARE area in
Table 2. Among healthy volunteers LDIFLARE area was smaller in
the univariate linear regression analysis with higher weight and
body mass index, higher HbA1c, and slower sural nerve
conduction velocity. Among subjects with type 1 diabetes,
LDIFLARE area was smaller in the univariate linear regression
analysis with with greater age, longer diabetes duration, higher
weight and body mass index, higher systolic blood pressure, higher
HbA1c, higher TCNS score and lower sural and peroneal nerve
conduction parameters. In multivariate analysis, the only variable
independently associated with lower LDIFLARE area in both
healthy volunteers and type 1 diabetes cohorts was higher HbA1c.
However, higher body mass index was additionally independently
associated with lower LDIFLARE area in healthy volunteers.
Discussion
In a relatively large cohort of healthy volunteers and type 1
diabetes subjects with a spectrum of nerve injury, we found that
there is a strong incremental association of smaller axon-mediated
neurogenic vascular flare response to cutaneous heating – as
measured by the LDIFLARE area – from healthy volunteers, non-
neuropathic type 1 diabetes subjects, and those with DSP. Despite
this relationship, we found insufficient diagnostic performance of
the LDIFLARE area for identification of DSP according to the
England clinical and electrophysiological criteria, indicated by an
area under the ROC curve of 0.72, and an optimal threshold value
for ruling in DSP of #1.90 cm
2 associated with sensitivity of 70%.
However, acknowledging limitations in the use of a later-stage
outcome measure for DSP that requires the presence of clinical
manifestations, we also investigated the diagnostic performance of
the LDIFLARE area for subclinical sural nerve impairment and
found higher accuracy (area under the ROC curve, 0.75) and
sensitivity (79%). Our analysis highlighted the importance of two
metabolic parameters that were independently associated with
LDIFLARE: greater glycemic exposure in diabetes subjects as well
as healthy volunteers, and higher body mass index in the healthy
volunteers.
There exists an urgent need to determine the early biomarkers
of DSP that could be used to predict individuals at risk of
subsequent clinically significant neuropathy in clinical practice,
but also for the evaluation of interventions for early nerve injury in
therapeutic clinical trials at the early stages when interventions are
most likely to be effective. The prevailing concept of the natural
history of DSP is that early nerve damage begins in small thinly
myelinated Ad and unmyelinated C-type nerve fibres [8,9], which
can be examined morphologically by quantification of intra-
epidermal nerve fibre density from skin biopsy [10], or by
Figure 1. Box-And-Whisker Plots Demonstrating The Distribu-
tion Of LDIFLARE Area In 64 Healthy Volunteers And 89 Type 1
Diabetes Subjects According To Neuropathy Status. Compared
to the healthy volunteer group LDIFLARE area was significantly smaller in
subjects with type 1 diabetes without DSP (p=0.006). Compared to
subjects with type 1 diabetes controls without DSP, LDIFLARE area was
smaller in cases with DSP (p=0.0.0002). As indicated in the figure,
among controls the LDIFLARE area was not different according to
presence or absence of subclinical sural nerve impairment. Similarly, the
LDIFLARE area was similar among cases with DSP regardless of severity.
The criteria for mild neuropathy were two or more abnormal nerve
conduction parameters in the lower limb (sural and peroneal nerve
distributions), and moderate and severe neuropathy were defined by
four and five abnormal parameters, respectively. NCS, nerve conduction
study. LDIFLARE, laser doppler imaging flare. DSP, diabetic sensorimotor
polyneuropathy.
doi:10.1371/journal.pone.0034807.g001
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cornea by confocal microscopy [23–26]. However, evaluation of
small fibre function – rather than its morphology – might offer a
valid measure of the early stages of DSP, and can be examined by
methods such as quantitative sensory testing and measurement of
axon reflex-mediated neurogenic vasodilatation [4,15,16,19,27–
31].
Neurogenic vasodilatation is directly related to nociceptive C-
fibre function, and application of a heating stimulus activates
othodromic transmission of these fibres, but also antidromic
transmission along branches of the same C-fibre that supply
surrounding cutaneous vessels. Additionally, there is suggestion
that the flare area is also induced by a dorsal root reflex [17]. In
the clinical evaluation of patients with painful DSP, the neurogenic
flare was frequently observed to be impaired even in the face of
normal quantitative sensory testing and normal morphology as
assessed by intra-epidermal nerve fibre density [16]. In support of
the attributes of the LDIFLARE area as an early DSP biomarker are
numerous small correlational studies [15,16,19,30,31].
The current study is among the first to evaluate the diagnostic
performance of LDIFLARE area in large groups of healthy
volunteers and individuals with type 1 diabetes and a wide
spectrum of nerve injury. Though it is cross-sectional in design, it
adds to the existing literature [15,16,19,30–32] and supports a
putative role for the measurement of the LDIFLARE area as a
diagnostic tool for early, small nerve dysfunction in diabetes
subjects. The deficiencies in its diagnostic performance shown in
this analysis must be considered in the context of the outcome
measure of clinical DSP according to the England criteria. The use
of an outcome measure reflecting an earlier phenotype of large
nerve fibre impairment in this study partially overcame deficien-
cies in diagnostic performance [33]. Given the absence of an
established gold-standard biomarker for early nerve damage
evaluated by longitudinal study, characterization of LDIFLARE
area as an early biomarker will be evaluated in the long-term
follow-up of this cohort. This follow-up will determine if an
LDIFLARE area value can predict future onset of neuropathy, the
ultimate indication that it represents incipient nerve impairment
that is clinically relevant. Until these results are available, however,
the current status of LDIFLARE as a diagnostic method for the
identification of DSP has substantial limitations.Whether using a
DSP definition weighted toward more advanced or less advanced
neuropathy severity, the sensitivity and specificity of the optimal
diagnostic threshold value are insufficient as independent
diagnostic tests. Rather than a diagnostic test, the role of
LDIFLARE may need to center on research studies designed to
determine the pathogenic stages, mechansims, and the natural
history of DSP.
Previous work has suggested a role for metabolic markers other
than glycemic exposure – such as serum triglycerides [31] –as
variables associated with the LDIFLARE area. Our analysis did not
identify an independent association of higher serum triglyceride
with lower LDIFLARE area, but did confirm the independent
association with worse glycemic control as indicated by higher
HbA1c levels. As a novel finding, we found an independent
association of higher body mass index with lower LDIFLARE area
in the healthy volunteer cohort, implying that this metabolic
parameter may affect small nerve function. However, we
acknowledge the alternate hypothesis that increased fat mass
might interfere with the technical measurement of the LDIFLARE
area owing to increased subcutaneous adipose tissue, and thus
increase the false positive rate for the identification of neuropathy
by this method. Further research into the LDIFLARE area will need
to reconcile the role of adiposity in the validity of this measure.
Although unique as a study of concurrent validity in DSP, we
acknowledge potential limitations to the interpretation of the
results in this study. First, we acknowledge that the most important
clinical outcome for the identification of early neuropathy
Figure 2. Receiver Operating Characteristic (ROC) Curves For The Identification Of Diabetic Sensorimotor Polyneuropathy (Panel A)
And Subclinical Sural Nerve Impairment (Panel B) By LDIFLARE Area In The 89 Subjects With Type 1 Diabetes. The ROC curve in Panel A
employed as the outcome the ‘‘England criteria’’ for DSP. Area under the curve was 0.72 and the threshold on the curve with optimal operating
characteristics (#1.90 cm
2 for ruling in cases, indicated by the asterisk) had a sensitivity of 66% and a specificity of 70%. The ROC curve in Panel B
employed as the outcome the ‘‘sural nerve criteria’’ to define an earlier stage of nerve impairment that did the ‘‘England Criteria’’ definition for DSP.
The area under the curve was 0.75and the single point on the curve with optimal operating characteristics (also #1.90 cm
2 for ruling in cases,
indicated by the asterisk) had a sensitivity of 79% and a specificity of 60%.
doi:10.1371/journal.pone.0034807.g002
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longitudinal study. The current cross-sectional analysis offers the
first step in this longitudinal research. Second, though we had
sufficient power to investigate important confounding relationships
in this study, we were limited by the number of variables in
multivariate analysis and could not confidently determine
independent associations with all of the nerve conduction study
parameters. Third, despite common features in the natural history
of type 1 and type 2 diabetes, further study is required to
determine the relevance of this data to type 2 diabetes. Fourth,
though we see a strong association of high-normal HbA1c with
lower LDIFLARE area in the healthy volunteers without diabetes,
we did not characterize their metabolic status by oral glucose
tolerance testing. However, neither their glucose parameters or
HbA1c values were consistent with a diagnosis of diabetes [34].
Finally, we did not systematically evaluate the maximum
hyperemia (LDImax) in the skin immediately beneath the heating
probe as performed by other investigators [31,35].
In summary, in view of limitations in the definition of clinical
neuropathy according to large fibre function, the current analysis
provides substantial confirmatory evidence for the putative role of
the evaluation of the neurogenic vascular flare as a biomarker of
early nerve dysfunction in the natural history of DSP. Its
independent association with glycemic exposure in diabetes
subjects and both glycemic exposure and BMI in healthy
volunteers highlights the existence of small-fibre dysfunction in
the natural history of DSP.
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Body mass index (kg/m
2) 20.18 0.01 20.03 0.39
*The multivariate model included the variables that were significant in univariate analysis in either the healthy volunteer of type 1 diabetes cohorts. Direct measures of
neuropathy – which included the TCNS and the nerve conduction studies – were not considered in the multivariate analysis.
HbA1c, glycated hemoglobin A1c.
doi:10.1371/journal.pone.0034807.t002
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